Ekso Bionics (NASDAQ:EKSO) Price Target Increased to $10.00 by Analysts at HC Wainwright

Ekso Bionics (NASDAQ:EKSO) had its price objective raised by HC Wainwright from $9.25 to $10.00 in a research note published on Tuesday, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Ekso Bionics’ Q2 2024 earnings at ($0.11) EPS, Q3 2024 earnings at ($0.09) EPS, Q4 2024 earnings at ($0.06) EPS, FY2024 earnings at ($0.43) EPS, Q1 2025 earnings at ($0.10) EPS, Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.19) EPS.

Separately, StockNews.com raised shares of Ekso Bionics from a sell rating to a hold rating in a research note on Thursday, April 4th.

Ekso Bionics Stock Performance

Shares of EKSO opened at $1.31 on Tuesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.81 and a quick ratio of 1.87. Ekso Bionics has a one year low of $0.62 and a one year high of $3.13. The company has a 50-day simple moving average of $1.44 and a two-hundred day simple moving average of $1.63. The firm has a market capitalization of $23.80 million, a PE ratio of -1.35 and a beta of 1.63.

Ekso Bionics (NASDAQ:EKSO) last announced its earnings results on Monday, April 29th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.04). Ekso Bionics had a negative net margin of 79.48% and a negative return on equity of 95.36%. The business had revenue of $3.76 million for the quarter, compared to the consensus estimate of $4.99 million. During the same period in the prior year, the business posted ($0.33) EPS. On average, analysts anticipate that Ekso Bionics will post -0.43 EPS for the current fiscal year.

Hedge Funds Weigh In On Ekso Bionics

An institutional investor recently bought a new position in Ekso Bionics stock. Kent Lake Capital LLC purchased a new stake in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 141,158 shares of the company’s stock, valued at approximately $353,000. Kent Lake Capital LLC owned approximately 0.95% of Ekso Bionics as of its most recent SEC filing. 6.42% of the stock is currently owned by institutional investors.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.